RMX1001

RMX1001 is a potent and highly selective small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (encoded by the SCN10A gene), currently under development by Hangzhou Ruomai Xingyi Pharmaceutical for the treatment of acute and chronic pain. Nav1.8 is primarily expressed in peripheral sensory neurons (nociceptors) and plays a critical role in the transmission of pain signals. By selectively blocking Nav1.8, RMX1001 aims to provide effective analgesia without the central nervous system side effects associated with opioids or the non-selective effects of traditional sodium channel blockers. The drug is being evaluated in clinical trials to address the significant unmet need for non-addictive pain management therapies.